GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turnstone Biologics Corp (NAS:TSBX) » Definitions » Debt-to-EBITDA

Turnstone Biologics (Turnstone Biologics) Debt-to-EBITDA : -0.03 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Turnstone Biologics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Turnstone Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.03 Mil. Turnstone Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.69 Mil. Turnstone Biologics's annualized EBITDA for the quarter that ended in Mar. 2024 was $-80.73 Mil. Turnstone Biologics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Turnstone Biologics's Debt-to-EBITDA or its related term are showing as below:

TSBX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.19   Med: -0.06   Max: 0.08
Current: -0.04

During the past 3 years, the highest Debt-to-EBITDA Ratio of Turnstone Biologics was 0.08. The lowest was -0.19. And the median was -0.06.

TSBX's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs TSBX: -0.04

Turnstone Biologics Debt-to-EBITDA Historical Data

The historical data trend for Turnstone Biologics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turnstone Biologics Debt-to-EBITDA Chart

Turnstone Biologics Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
0.08 -0.19 -0.06

Turnstone Biologics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.73 -0.05 -0.05 -0.05 -0.03

Competitive Comparison of Turnstone Biologics's Debt-to-EBITDA

For the Biotechnology subindustry, Turnstone Biologics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Turnstone Biologics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turnstone Biologics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Turnstone Biologics's Debt-to-EBITDA falls into.



Turnstone Biologics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Turnstone Biologics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.025 + 1.189) / -56.234
=-0.06

Turnstone Biologics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.025 + 0.691) / -80.728
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Turnstone Biologics  (NAS:TSBX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Turnstone Biologics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Turnstone Biologics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Turnstone Biologics (Turnstone Biologics) Business Description

Traded in Other Exchanges
N/A
Address
9310 Athena Circle, Suite 300, La Jolla, CA, USA, 92037
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
Executives
Davis Jerel director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert J Gould director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Sammy J. Farah director, officer: President & CEO C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Saryah Azmat officer: Chief Business Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Venkat Ramanan officer: Chief Financial Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Campisi Peter Joseph Jr. officer: Chief Legal Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Vijay Chiruvolu officer: Int. Chief Technology Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kanya Rajangam director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Versant Ventures V Gp-gp (canada), Inc. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Michael F. Burgess director, officer: Interim Chief Medical Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stewart Abbot officer: Chief Scientific Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037